Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$180.40

4.75 (2.70%)

05:31
05/07/19
05/07
05:31
05/07/19
05:31

GW Pharmaceuticals price target raised to $210 from $185 at Piper Jaffray

Piper Jaffray analyst Danielle Brill raised her price target for GW Pharmaceuticals to $210 from $185 after Epidiolex sales in Q1 of $33.5M "solidly beat" her $20.7M estimate. Epidiolex's growth trajectory will continue over the coming quarters given expected launch in Europe, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications, Brill tells investors in a research note. She expects GW's momentum to continue and reiterates an Overweight rating on the shares.

  • 29

    May

GWPH GW Pharmaceuticals
$180.40

4.75 (2.70%)

03/04/19
PIPR
03/04/19
NO CHANGE
PIPR
Piper Jaffray sees continued medical cannabis growth
Piper Jaffray analyst Michael Lavery writes that his discussions with a medical pain specialist in New York affirm his expectations of continued growth for medical cannabis, particularly as practitioners search for opioid alternatives. With over 30 U.S. states now in favor of medical use of marijuana, the analyst believes that the national prohibition will end in the next few years with the "STATES Act or federal legalization". Lavery is positive on Tilray (TLRY) and its partnership with Novartis (NVS) to develop and distribute medical cannabis products, keeping his Overweight rating and $90 price target on the shares. The analyst also calls GW Pharma (GWPH) a "trailblazer for developing cannabis-derived products for medical use", with its FDA-approved epidiolex cannabidiol product, keeping his Overweight rating and $195 price target on the stock. Lavery further maintains his Overweight rating and $60 price target on Canopy Growth (CGC) given its current valuation.
04/09/19
MSCO
04/09/19
NO CHANGE
Target $227
MSCO
Overweight
GW Pharma shares should rise 5%-10% on Zogenix delay, says Morgan Stanley
Morgan Stanley analyst David Lebowitz said he expects shares of GW Pharmaceuticals (GWPH) to be up at least 5-10% on the open following news that Zogenix (ZGNX) was issued a Refusal to File letter for Fintepla by the FDA. The RTF delays a potential competing product for Epidiolex for the treatment of seizures associated with Dravet Syndrome, Lebowitz explained. While he lacks visibility, Lebowitz said he would expect a delay of 3-6 months on the short end if Zogenix can use historic toxicity data and a delay of up to 15 months if the FDA requires new toxicity studies. Lebowitz keeps an Overweight rating on GW Pharmaceuticals shares, which are up 4% to $174.85 in pre-market trading.
04/16/19
PIPR
04/16/19
NO CHANGE
Target $185
PIPR
Overweight
GW Pharmaceuticals shares can rally 15% on imminent data, says Piper Jaffray
The pivotal Phase 3 data with epidiolex for seizures related to tuberous sclerosis complex are imminent, yet it's hard to gauge how much investors care, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst models a 50% probability of success for tuberous sclerosis complex and sees ~15% share upside if the data support label expansion. However, Brill adds that if safety looks clean and higher doses drive better efficacy, peak sales could be double her $400M estimate, driving potential upside of 20%-25%. If efficacy and/or safety signals occur that prevent label expansion for tuberous sclerosis complex, she estimates share downside of ~15%. This could be "substantially more" with a severe safety signal that broadly prohibits off-label use, however, the analyst adds. Brill has an Overweight rating on GW Pharmaceuticals with a $185 price target.
04/29/19
OPCO
04/29/19
NO CHANGE
Target $162
OPCO
Perform
GW Pharmaceuticals price target raised to $162 from $142 at Oppenheimer
Oppenheimer analyst Esther Rajavelu raised her price target for GW Pharmaceuticals to $162 from $142 following a brief poll to screen for prescribers' views on Epidiolex and gauge potential for broader uptake. The analyst notes that a majority of respondents have prescribed Epidiolex to less than 5% of patients, however, they consider it equally as/more effective than other therapies. Further, most have had less than 10% of treated patients experience adverse events, an almost equal proportion of prescribers manage AEs by reducing Epidiolex or other medications, and over next 12-18 months, most respondents plan to increase Epidiolex prescriptions, she adds. Rajavelu continues to view GW Pharmaceuticals as a good launch story. She reiterates a Perform rating on the shares.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.